Company Overview
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia.
Key Financial Figures
For the fourth quarter and year ended December 31, 2025, LENZ reported net product sales revenue of $1.6 million. The company reported a basic and diluted net loss per share of $1.16 per share for the fourth quarter, and $2.85 per share for the full year 2025.
Additional Financial Insights
As of December 31, 2025, cash, cash equivalents, and marketable securities were $292.3 million. Selling, general, and administrative (SG&A) expenses were $91.1 million for the year ended December 31, 2025, driven primarily by preparations for and the execution of the commercial launch of VIZZ.
The post LENZ Therapeutics Q4 FY 2025 Financial Update first appeared on Alphastreet.
